Elafibranor

Elafibranor (INN,^[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).^[3][4][5]

Elafibranor

Clinical data
Other names	GFT505, SureCN815512
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[2,6 Dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)-propenyl]phenoxyl]-2-methylpropanoic acid^[1]
CAS Number	923978-27-2
PubChem CID	9864881
ChemSpider	8040573
UNII	2J3H5C81A5
Chemical and physical data
Formula	C22H24O4S
Molar mass	384.49 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C(Oc1c(cc(cc1C)\C=C\C(=O)c2ccc(SC)cc2)C)(C)C
InChI InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+ Key:AFLFKFHDSCQHOL-IZZDOVSWSA-N

Elafibranor is a dual PPARα/δ agonist.^[6][7]

See also

• MBX-8025
• Resveratrol
• Telmisartan

References

1. Cariou B, Zaïr Y, Staels B, Bruckert E (September 2011). "Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism". Diabetes Care. 34 (9): 2008–14. doi:10.2337/dc11-0093. PMC 3161281. PMID 21816979.
2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. p. 10. (PDF) from the original on 10 November 2016. Retrieved 9 November 2016.
3. "Advanced Compound Status" (Press release). Genfit. Archived from the original on 2013-04-11.
4. "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). (PDF) from the original on 10 July 2021. Retrieved 31 Mar 2013.
5. Cariou B, Staels B (October 2014). "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs. 23 (10): 1441–8. doi:10.1517/13543784.2014.954034. PMID 25164277. S2CID 3190253.
6. US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641" (PDF). Retrieved 31 Mar 2013.
7. Vázquez-Carrera, M. (2012). "GFT-505" (PDF). Drugs of the Future. 37 (8): 555–559. doi:10.1358/dof.2012.037.08.1835977. S2CID 258323049.^{[permanent dead link]}

External links

• Genfit Pharmaceutical
• NashBiotechs Several articles on drug candidates in NASH